GleamWall
中文EN

IMNM Immunome Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1472012 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-63.3%
TTM net income YoY-9.5%
TTM EPS YoY20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,947.9%
Net margin-5,593.8%
FCF margin-5,118.9%
EBITDA margin-5,886.7%

Returns

ROE-50.1%
ROA-46.7%
ROIC (approx.)-679.8%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets5.0%
Debt / equity0.00x
Current ratio21.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue224.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$4.01M$2.93M$2.74M
R&D expense$69.51M$59.88M$46.38M$50.77M$49.19M$40.45M$36.87M$47.89M
SG&A expense$20.86M$18.25M$12.95M$12.09M$10.95M$10.04M$10.69M$10.45M
Operating income-$90.36M-$78.14M-$59.33M-$72.86M-$60.14M-$46.48M-$44.64M-$82.97M
Net income-$85.78M-$73.13M-$53.84M-$69.90M-$57.46M-$43.40M-$41.64M-$80.25M
EBITDA-$89.36M-$77.18M-$58.73M-$72.23M-$59.55M-$45.84M-$44.02M-$82.52M
EPS (basic)-0.76-0.65-0.48—-0.65-0.50-0.52—
EPS (diluted)-0.76-0.65-0.48—-0.65-0.50-0.52—
Weighted avg. shares (diluted)113.56M113.27M113.14M—87.96M87.01M79.41M—
Banking
Net interest income$4.58M$5.01M$5.49M$2.96M$2.68M$3.08M$3.00M$2.72M
Balance sheet
Cash & equivalents$212.84M$217.71M$582.69M$653.48M$272.64M$143.88M$257.61M$143.45M
Short-term investments$248.74M$302.29M—$0$0$124.16M$59.71M$73.95M
Current assets$477.80M$538.45M$594.31M$660.78M$279.92M$277.43M$323.13M$221.34M
PP&E, net$16.67M$17.36M$17.08M$14.64M$11.56M$11.03M$10.95M$10.11M
Total assets$505.53M$565.38M$619.79M$683.19M$299.38M$296.29M$342.69M$240.24M
Current liabilities$40.97M$35.71M$27.41M$44.99M$31.45M$22.88M$30.80M$54.31M
Total liabilities$51.22M$40.30M$31.11M$48.84M$35.46M$27.02M$35.57M$59.08M
Shareholders' equity$454.30M$525.08M$588.69M$634.34M$263.92M$269.27M$307.13M$181.16M
Shares outstanding113.65M113.40M113.17M113.13M91.71M87.01M86.96M64.46M
Cash flow statement
Operating cash flow-$60.75M-$61.69M-$58.64M-$47.95M-$40.51M-$49.40M-$53.05M-$42.06M
Capital expenditure$489,000$2.18M$3.00M$4.00M$1.12M$905,000$3.67M$1.13M
Free cash flow-$61.24M-$63.87M-$61.64M-$51.95M-$41.63M-$50.31M-$56.72M-$43.19M
Investing cash flow$53.51M-$304.35M-$12.02M-$4.00M$123.88M-$64.17M$5.09M$9.76M
Financing cash flow$2.38M$1.06M-$135,000$432.80M$45.39M-$55,000$162.23M$20.09M
Depreciation & amortization$1.00M$957,000$603,000$629,000$589,000$637,000$611,000$450,000
Stock-based compensation$12.76M$8.80M$7.95M$7.89M$6.75M$5.35M$5.70M$5.47M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.